To examine the role of the mitochondrial polymerase (Pol ␥) in clinically observed toxicity of nucleoside analogs used to treat AIDS, we examined the kinetics of incorporation catalyzed by Pol ␥ for each Food and Drug Administration-approved analog plus 1-(2-deoxy-2-fluoro-␤-D-arabinofuranosyl)-5-iodouracil (FIAU), ␤-L-(؊)-2,3-dideoxy-3-thiacytidine (؊)3TC, and (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA). We used recombinant exonuclease-deficient (E200A), reconstituted human Pol ␥ holoenzyme in single turnover kinetic studies to measure K d (K m ) and k pol (k cat ) to estimate the specificity constant (k cat /K m ) for each nucleoside analog triphosphate. The specificity constants vary more than 500,000-fold for the series ddC > ddA (ddI) > 2,3-didehydro-2,3-dideoxythymidine (d4T) > > (؉)3TC > > (؊)3TC > PMPA > azidothymidine (AZT) > > Carbovir (CBV). Abacavir (prodrug of CBV) and PMPA are two new drugs that are expected to be least toxic. Notably, the higher toxicities of d4T, ddC, and ddA arose from their 13-36-fold tighter binding relative to the normal dNTP even though their rates of incorporation were comparable with PMPA and AZT. We also examined the rate of exonuclease removal of each analog after incorporation. The rates varied from 0.06 to 0.0004 s ؊1 for the series FIAU > (؉)3TC ϳ (؊)3TC > CBV > AZT > PMPA ϳ d4T > > ddA (ddI) > > ddC. Removal of ddC was too slow to measure (<0.00002 s ؊1 ). The high toxicity of dideoxy compounds, ddC and ddI (metabolized to ddA), may be a combination of high rates of incorporation and ineffective exonuclease removal. Conversely, the more effective excision of (؊)3TC, CBV, and AZT may contribute to lower toxicity. FIAU is readily extended by the next correct base pair (0.13 s ؊1 ) faster than it is removed (0.06 s ؊1 ) and, therefore, is stably incorporated and highly mutagenic. We define a toxicity index for chain terminators to account for relative rates of incorporation versus removal. These results provide a method to rapidly screen new analogs for potential toxicity.
Current treatment of HIV 1 includes a mixture that generally consists of a combination of nucleoside and nonnucleoside analogs directed against HIV RT, plus an inhibitor of HIV protease. Treatment with this mixture allows patients to coexist with a low level of virus for years, but treatments are limited by the development of resistance of HIV to the drugs on the one hand and toxicity of nucleoside analogs on the other. Toxicity of nucleoside analogs is particularly troublesome for the long term management of the viral infection. Nucleoside analogs function as chain terminators to suppress viral replication by HIV-1 RT, and because HIV RT lacks a proofreading exonuclease, the specificity of nucleoside analogs toward HIV RT results from selective discrimination during incorporation and/or from removal by the proofreading exonuclease of the host DNA polymerase.
Six nucleoside analogs have received Food and Drug Administration approval for treatment of HIV, and these analogs are illustrated with others in Fig. 1 . All of these analogs act to halt viral replication by chain termination since they each lack a 3Ј-OH. There is growing evidence that these analogs also act as substrates for human mitochondrial DNA polymerase (Pol ␥), resulting in inhibition of mitochondrial replication (1) (2) (3) (4) (5) . Patients experience side effects due to toxicity of these drugs, which are, in part, caused by interaction with Pol ␥ (2, 6). The differences in analog toxicity may result from a combination of cellular uptake (7), organellar transport (2), metabolic activation (7), incorporation, (7) and removal or degradation from the system (2) . Generally, the individual contributions of these factors to analog toxicity is unknown.
General symptoms of nucleoside analog toxicity include peripheral neuropathy (seen with 2Ј,3Ј-didehydro-2Ј,3Ј-dideoxythymidine (d4T), ddI, and ddC), myopathy, and bone marrow suppression (seen with 3Ј-azido-2Ј,3Ј-dideoxythymidine (AZT)), and pancreatitis (seen with ddI) (8) . Many of the side effects resulting from nucleoside analog treatment mimic the symptoms of mitochondrial diseases caused by genetic defects (4) . Moreover, loss of mitochondrial DNA and changes in mitochondrial ultrastructure have been observed in cell culture studies after treatment with nucleoside analogs (9 -16) . A summary of symptoms resulting from mitochondrial diseases and the nucleoside analogs that can cause these symptoms is presented in 1 The abbreviations used are: HIV-1 RT, human immunodeficiency virus-1 reverse transcriptase; Pol ␥, DNA polymerase ␥; dNTP, deoxynucleoside triphosphate; d4T, 2Ј,3Ј-didehydro-2Ј,3Ј-dideoxythymidine; ddA, 2Ј,3Ј-dideoxyadenosine; ddI, 2Ј,3Ј-dideoxyinosine; AZT, 3Ј-azido-2Ј,3Ј-dideoxythymidine; FIAU, 1-(2-deoxy-2-fluoro-␤-d-arabinofuranosyl)-5-iodouracil; CBV, (Ϫ)-cis-2-amino-1,9-dihydro-9-(4-hydroxymethyl)-2-cyclopenten-1-yl)-6H-purine-6-one; PMPA, (R)-9-(2-phosphonylmethoxypropyl)adenine; PMPApp, triphosphate of PMPA; SIV, simian immunodeficiency virus; (Ϫ)3TC, ␤-L-(Ϫ)-2Ј,3Ј-dideoxy-3Ј-thiacytidine. Table I (17) . With the exception of 1-(2-deoxy-2-fluoro-␤-D-arabinofuranosyl)-5-iodouracil (FIAU), which is not a chain terminator, these side effects are reversible upon withdrawal of drug treatment, suggesting removal of the chain terminators from the mitochondrial DNA and restoration of normal rates of replication.
Nucleoside analog toxicity has been studied extensively in animal and cell culture models. Studies using cell lines with compartment-specific kinases showed that nucleoside analogs that were phosphorylated in the mitochondria became trapped in this compartment and that the location of phosphorylation was important in determining whether an analog was incorporated into mitochondrial or nuclear DNA (18) . These data are useful in analyzing overall drug toxicity, but the differences in nucleoside analog phosphorylation and the number of mitochondria per cell are based on the energetic requirements of each cell type, which can lead to a considerable variation of observed cell-and organ-specific toxicity.
Structure/function studies with nucleoside analogs and Pol ␥ may provide useful insight for design of less toxic, viral polymerase-specific analogs. We have examined the interactions between human Pol ␥ and nucleoside analogs during in vitro polymerization to evaluate the possible mechanistic basis of nucleoside analog toxicity. To provide directly quantifiable data, we have performed transient kinetic studies to carefully examine the kinetics of incorporation of each of the nucleoside analog triphosphates by Pol ␥ and to compare with our previous analysis of HIV . 
MATERIALS AND METHODS
The nucleoside analogs in this study were the triphosphate forms of d4T (Stavudine); 2Ј,3Ј-dideoxyadenosine (active form of ddI, Didanosine); AZT (Zidovudine); FIAU; (Ϫ)-cis-2-amino-1,9-dihydro-9-(4-hydroxymethyl)-2-cyclopenten-1-yl)-6H-purine-6-one (Carbovir, CBV, active form of Abacavir); and (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA, Tenofovir disoproxil fumarate). ddATP was obtained from Sigma, whereas d4TTP and AZTTP were obtained from Moravek Biochemicals (Brea, CA). PMPApp and CBVTP were kind gifts of Gilead Sciences (Foster City, CA) and Dr. William B. Parker (Southern Research Institute, Birmingham, AL), respectively.
Overexpression and purification of recombinant human Pol ␥ were previously described (22, 23) . Holoenzyme was reconstituted at a 1:5 ratio of catalytic subunit to accessory subunit. All of the studies on the kinetics of incorporation of nucleoside analog triphosphates were conducted using an exonuclease-deficient mutant (E200A). This mutant was selected based upon studies showing that this single point mutation did not alter the kinetics of normal nucleotide incorporation (data not shown). All other studies were conducted using wild-type enzyme.
A DNA primer/template of 25 and 45 nucleotides, respectively, was employed for all experiments except for CBV incorporation and excision. The primer sequence was 5Ј-GCCTCGCAGCCGTCCAACCAACT-CA-3Ј, and the template sequence was 5Ј-GGACGGCATTGGATCGAG-GTTGAGTTGGTTGGACGGCTGCGAGGC-3Ј. The template sequence opposite the 26th primer position was altered to allow correct base pairing for each analog incorporation reaction. The 30-mer primer utilized for CBVTP experiments was 5Ј-GCCTCGCAGCCGTCCAAC-CAACTCAACCTC-3Ј, and the corresponding 45-mer template was used. Primers were 5Ј-32 P-labeled with T4 polynucleotide kinase according to the manufacturer's instructions (Life Technologies, Inc.). The reaction was terminated by incubation at 95°C for 5 min. Unincorporated nucleotide was removed using a Bio-Spin 6 column (Bio-Rad). Primer was annealed to 45-mer template by combining at an equimolar ratio, heating to 95°C, and cooling to room temperature.
Primers containing 3Ј-terminal nucleoside analog residues were created to examine excision of each analog. A polymerase reaction was performed using 1 M polymerase, 3 M duplex DNA (containing appropriate template base opposite 26th primer position), and 50 M analog in standard reaction buffer (50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 2.5 mM MgCl 2 ). Primer terminated with ddAMP, 2 ddIMP, and FIAUMP were created using Pol ␥, and HIV-1 RT was used for primers terminated in AZTMP, CBVMP, or d4TMP. Reaction mixtures were incubated at 37°C for 30 min, and then the products were gel-purified to obtain the analog-terminated primer. Primers were labeled, and DNA duplexes were annealed as described above.
All polymerase assays were performed at 37°C in buffer containing 50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 2.5 mM MgCl 2 . The holoenzyme was reconstituted by incubating the two protein subunits for 20 min on ice in reaction buffer lacking magnesium. DNA was then added to the proteins, and the mixture was incubated for an additional 20 min on ice. Reactions were initiated by the addition of nucleotide and magnesium in the same reaction buffer at 37°C and then quenched with 0.3 M EDTA. Alternatively, only magnesium was added to initiate excision reactions. All concentrations given are final reaction conditions. Polymerase and excision assay products were separated on 15% denaturing polyacrylamide sequencing gels, imaged on a Storm 860, and quantified using ImageQuaNT software (Molecular Dynamics, Sunnyvale, CA) or a Bio-Rad GS525 Imager using Molecular Analyst (Bio-Rad). Ϫkt ϩ C). The observed rates were then plotted against nucleotide concentrations, and the data were fit to a hyperbola (observed rate ϭ
) to obtain the K d and the maximum rate of polymerization, k pol , for each nucleoside analog. A quadratic equation was used to fit the rate data for d4TTP and ddCTP incorporation due to the tightness of nucleotide binding Ϫkt ϩ C, where k represents the rate of excision (k exo ) in a single turnover.
RESULTS
Incorporation of nucleoside analogs into DNA by Pol ␥ was investigated to determine the kinetic parameters governing enzyme discrimination against incorporation of these substrates based upon the supposition that those most easily incorporated and most difficult to remove would be the most toxic. Single turnover conditions were employed in that the concentration of enzyme was in excess of the concentration of DNA. Kinetic studies on Pol ␥ and every other DNA polymerase examined with natural deoxynucleoside triphosphate substrates have shown that the pre-steady state burst of polymerization defines the rate of incorporation, whereas the slower steady state rate is limited by the rate of dissociation of DNA from the enzyme (23) (24) (25) (26) (27) (28) (29) (30) . By restricting our attention to the first turnover and examining the reaction on a millisecond time scale, we circumvent the slower reactions, limiting the steady state measurements on processive enzymes.
For each analog, the concentration dependence of the rate of incorporation was obtained from a series of polymerization experiments performed at various nucleotide concentrations. The concentration dependence defines the K d for ground state nucleotide binding and the maximum rate, k pol , for incorporation. Based upon knowledge of the mechanism of the reaction, these parameters define the K m and k cat , respectively, for incorporation and the ratio k pol /K d ϭ k cat /K m , the specificity constant, because nucleotide binding is a rapid equilibrium step and is followed by a single rate-limiting incorporation reaction (25) .
The concentration dependence of d4TTP incorporation by Pol ␥ is illustrated in Fig. 2A . The rate of incorporation was established by a fit to a single exponential at each nucleotide concentration. The nucleotide concentration dependence of the rate (Fig. 2B ) was fit to a quadratic equation to yield a K d for ground state binding for d4TTP of 44.7 Ϯ 7.5 nM and a maximum rate of polymerization of 0.24 Ϯ 0.01 s Ϫ1 (Fig. 2B ). The data had to be fit to a quadratic equation rather than a hyperbola because the K d was less than the concentration of enzyme-DNA used in the experiment. Importantly, the tight binding of d4TTP makes this analog highly competitive for incorporation by Pol ␥ as defined by the specificity constant (Table II) even though its rate of incorporation is not large.
Approximately 3% of ddI intracellularly converts to ddATP, the active form of the drug (31, 32) . Therefore, to examine the toxicity of ddI, we examined the kinetics of incorporation of ddATP. The ground state nucleotide binding and maximum polymerization rate for ddATP incorporation were 0.022 Ϯ 0.009 M and 0.31 Ϯ 0.02 s Ϫ1 , respectively (Fig. 3 , Table II ). For completeness, we include the results of studies on ddI in summary Tables II and IV (primary data not shown).
The active form of Abacavir is CBVTP. Incorporation of CB-VTP occurred at a maximum polymerization rate of 0.0018 Ϯ 0.0001 s Ϫ1 , with a ground state nucleotide binding of 13 Ϯ 1.5 M (Fig. 4 , Table II ). The maximum rate of incorporation of CBVTP was the slowest we observed for the analogs in this study (Fig. 4 , Table II ). Pre-steady state burst experiments in which primer/template is in slight excess of enzyme were used to show that the rate-limiting step for CBVTP incorporation had changed from the release of product to catalysis (Fig. 4A ) due to the lack of a burst. With DNA in excess, natural dNTPs and most nucleoside analog triphosphates show a pre-steady state burst under these conditions reflecting fast catalysis followed by slow release of product, as illustrated by the results of a similar experiment with dGTP (see inset to Fig. 4A ).
The kinetics of AZTTP incorporation by Pol ␥ were unusual in that there was no dependence of the rate on nucleotide concentration. A plot of the rate of incorporation against nucleotide incorporation illustrates a higher degree of error when fitting data for lower concentrations of AZTTP (Fig. 5B ) due to the low amplitude of this reaction. Unlike all other nucleotides and analogs investigated, the amplitude of the AZT incorporation reaction was concentration-dependent ( Fig. 5C ). Fitting the concentration dependence of the amplitude provided an estimate of the ground state binding of the analog of 187.3 Ϯ 53.9 M. A maximal rate of incorporation of ϳ0.2 s Ϫ1 was estimated from the rate data for determination of the specificity constant for AZTTP incorporation. However, because the kinetics of incorporation for AZTTP differ from other analogs, these numbers do not simply relate to k cat and K m to define discrimination as do the data for other analogs (see "Discussion").
PMPA is a drug that is currently in third-phase clinical trial by Gilead Sciences. The kinetics of incorporation of PMPApp are shown in Fig. 6 . PMPApp was incorporated at a maximum rate of 0.21 Ϯ 0.01 s Ϫ1 , with a ground state binding of 40.3 Ϯ 5.7 M.
FIAU was developed to treat hepatitis B infection, but the severe side effects led to the death of five patients in the initial clinical trial (33) . Toxic side effects of FIAU have been shown by extensive studies to be related to mitochondrial toxicity (34) . We analyzed incorporation, extension, and removal of FIAUTP by Pol ␥ to establish the kinetic parameters underlying the severe toxicity of this compound. Incorporation of FIAUTP occurred at a rate of 24 Ϯ 2 s Ϫ1 , with ground state binding of 2.9 Ϯ 0.7 M (Fig. 7) . The rate of incorporation of this analog was the same as incorporation of the natural substrate, dTTP, with 5-fold weaker binding of the analog (0.63 M ground state binding for dTTP (24) ) so that overall discrimination was only 4.8. Additionally, FIAUTP contains a 3Ј OH that allows internalization of the analog into the DNA after formation of the next base pair. Incorporation of dCTP onto a primer containing a 3Ј FIAUMP occurred at a rate of 0.13 Ϯ 0.01 s Ϫ1 with a ground state nucleotide binding of 0.83 Ϯ 0.20 M (Fig. 8) .
Incorporation of dCTP after a natural nucleotide by Pol ␥ occurred at a rate of 43 s Ϫ1 , with a K d of 0.91 M (24). Therefore, the presence of FIAUMP had no effect on next correct nucleotide binding, but the rate of polymerization was decreased 300-fold, which may allow time for the exonuclease removal depending upon the rate of excision versus extension (see discussion). The important conclusion is that FAIU can be extended so that it becomes stably incorporated into the mitochondrial genome, confirming earlier work showing the incorporation of FIAU into mitochondrial DNA in vivo (35) .
A summary of the polymerization parameters for each nucleoside analog examined is presented in Table II . Data from three previously analyzed dCTP analogs are included for comparison (36) . Pol ␥ incorporates natural nucleotides at an average polymerization rate of 37 s Ϫ1 , with an average ground state nucleotide binding of 0.8 M using 25/45 DNA (24). The specificity constants for dTTP and dATP incorporation are calculated from the kinetic parameters as previously reported (23, 24) . The same substrate DNA was used for analyzing incorporation of d4TTP, ddATP, AZTTP, and PMPApp. CBVTP incorporation was examined using 30/45 DNA, and the corresponding parameters for dGTP incorporation are provided in the footnote of Table II . The specificity constants were calculated by dividing the polymerization rate by the ground state dissociation constant for each analog. The ability of the polymerase to select the natural nucleotide during polymerization was calculated from a ratio of the specificity constants for the correct nucleotide and its corresponding analog. For example, Pol ␥ discriminates against d4TTP incorporation by a factor of 7.4, as determined from the specificity constants of 39.7 (25 s Ϫ1 / 0.63 M) and 5.4 for dTTP and d4TTP, respectively.
Kinetics of Excision-Hydrolysis of each analog from the 3Ј end of the primer in duplex DNA was examined to determine the effectiveness of the exonuclease activity of Pol ␥ in removing nucleoside analogs after their incorporation. A reaction was performed to add each analog onto the 3Ј end of the 25-or 30-mer primer. After annealing the purified primer to 45-mer template, excision of the analogs was examined using single turnover conditions (enzyme in excess). Excision reactions were monitored over 1.5 h for primers terminated in AZTMP, ddAMP, d4TMP, CBVMP, and PMPA. The rates of excision of these analogs were slow, in the range of 0.022-0.099 min Ϫ1 (Fig. 9A) . Due to the slow rates of excision of these analogs, dissociation of the DNA is likely to occur after incorporation and before hydrolysis. Excision of PMPA-26/45 DNA in the presence of a DNA trap resulted in no observable cleavage, indicating that the slow excision rate or weak substrate bind- ing allows dissociation to occur before removal of the analog (data not shown). Dissociation of the chain-terminated DNA before exonuclease action may contribute to the observed toxicity in mitochondria.
The rate of excision of FIAUMP from duplex DNA occurred at a faster rate of 0.06 s Ϫ1 (Fig. 9B) , similar to the rate of excision of a correctly base-paired nucleotide (0.05 s Ϫ1 (37)). A large fraction of DNA containing 3Ј PMPA, ddAMP, and d4TMP failed to undergo hydrolysis, whereas excision of AZTMP and CBVMP from the DNA approached an amplitude of 100% of the DNA. We do not understand why some reactions fail to go to completion, so the nature of the excision reaction clearly needs to be studied further. Our best estimates of the rates of excision of each analog are summarized in Table IV for removal of each of the analogs from the 3Ј end of the primer in the primer/template duplex.
DISCUSSION
Loss of mitochondrial DNA, changes in mitochondrial ultrastructure, and side effects resembling symptoms of diseases caused by mutations in mitochondrial DNA all suggest that at least some of the toxicity of antiviral nucleoside analogs results from inhibition of mitochondrial replication (4, 10 -13). The incorporation of several nucleoside analogs by Pol ␥ was analyzed to examine the mechanistic basis of clinically observed mitochondrial toxicity of these analogs. We analyzed the strength of analog ground state binding (K d ), the maximum rate of polymerization (k pol ), and the rate of excision (k exo ) of six nucleoside analogs. Together with previously published data describing these parameters for ddCTP and (ϩ)-and (Ϫ)-3TCTP (36), the interactions of all of the currently approved anti-HIV nucleoside analogs with Pol ␥ are now compared. Additionally, PMPA is in third-phase clinical trial, and preliminary results indicate the analog is effective at suppression of viral replication in humans (38) and macaques with chronic simian immunodeficiency virus (SIV) infection (39) . Recent studies suggest PMPA also successfully allows the development of an antiviral immune response in SHIV KU (pathogenic SIV/HIV hybrid)-infected rhesus macaques (40, 41) . Our studies and current clinical progress suggest that PMPA is among the least toxic of the currently available nucleoside analogs.
Treatment of hepatitis B patients with FIAU resulted in five fatalities that were thought to result from severe mitochondrial toxicity (33) . We included FIAUTP in this study as an example of a drug that may serve as a "good" substrate for polymerization by Pol ␥ and, therefore, be highly toxic. Moreover, given the rates of extension (0.13 s Ϫ1 ) versus excision (0.06 s Ϫ1 ), 68% of the incorporated FIAU will be extended rather than removed by the proofreading exonuclease. Once stably incorporated, it may likely serve as a potent mutagen by altering dNTP selectivity or DNA topology (43) . In the case of mitochondrial toxicity, the use of an Ames test to evaluate mutagenicity may not be valid since the test relies upon the fidelity of different DNA polymerases.
Recognition of the differences between the structures of natural nucleotides and the analogs provides the structural basis for discrimination by the polymerase during substrate selection at the enzyme active site. With the exception of FIAUTP, the analogs in this study lack the 3Ј-OH required for DNA chain extension. The lack of a 3Ј-OH allows nucleoside analogs to simply act as chain terminators. In addition, CBVTP and 
FIG. 3. Ground state binding and maximum rate of polymerization for ddATP incorporation.
A, holoenzyme (100 nM) was preincubated with 90 nM 25/45 DNA and then rapidly mixed with magnesium and various concentrations of nucleotide (0.01 (f), 0.05 (E), 0.1 (q), 0.5 (Ⅺ), 5 (‚),10 M (OE), and 25 M (ƒ)). Each data set was fit to a single exponential to derive k obs , the rate of the incorporation reaction. B, the single exponential rates were plotted as a function of ddATP concentration. The fit of the data to a quadratic yields a K d of 22 Ϯ 9 nM and a maximum polymerization rate, k pol , of 0.31 Ϯ 0.02 s Ϫ1 .
d4TTP have a 2Ј,3Ј-unsaturated bond, and the presence of this double bond apparently leads to increased affinity of similar analogs to DNA polymerases (44, 45) . In PMPA, an acyclic phosphonate group replaces the ribose. The absence of a ribose in PMPApp makes the observation of incorporation by any polymerase a remarkable discovery. Nonetheless, it is efficiently incorporated by HIV-1 RT (19), but not by Pol ␥, making it a highly effective inhibitor, although it may be less effective than predicted if there are problems in uptake and/or phosphorylation. Incorporation of the three cytosine analogs by Pol ␥ was previously studied (36) . (Ϫ)3TC contains the unnatural L(Ϫ) nucleoside configuration. Cell culture studies show that (Ϫ)3TC is less toxic than (ϩ)3TC, the D(ϩ) isomer, and both are considerably less toxic than ddC (46) . The unnatural L(Ϫ) configuration of (Ϫ)3TC seems to play an important role in pre- FIG. 4 . Ground state binding and maximum rate of polymerization for CBVTP incorporation. A, holoenzyme (50 nM) was preincubated with 250 nM 30/45 DNA and then rapidly mixed with magnesium and various concentrations of nucleotide (20 (q), 100 (E) M) in a pre-steady state burst reaction. Although reactions with natural dNTPs (4 M dGTP is shown in the inset) and most analogs show a burst of rapid product formation according to the rate of catalysis (for 4 M dGTP 130 s Ϫ1 ) followed by a slow steady state rate according to the overall rate-limiting step of the reaction (product release), CBVTP only showed a linear increase in product formation, illustrating that there has been a change in the overall rate-limiting step of the reaction. B, holoenzyme (50 nM) was preincubated with 45 nM 30/45 DNA and then rapidly mixed with magnesium and various concentrations of nucleotide (5 (E), 10 (q), and 60 (Ⅺ) M). Each data set was fit to a single exponential to derive k obs , the rate of the incorporation reaction. C, the incorporation rates were plotted as a function of CBVTP concentration. The fit of the data to a hyperbola yields a K d of 13.4 Ϯ 1.5 M and a maximum polymerization rate, k pol , of 0.018 Ϯ 0.001 s Ϫ1 .
FIG. 5. Ground state binding and maximum rate of polymerization for AZTTP incorporation.
A, holoenzyme (100 nM) was preincubated with 90 nM 25/45T DNA and then rapidly mixed with magnesium and various concentrations of nucleotide (50 (E), 100 (q), 150 (Ⅺ), 250 (f), 325 (‚), and 400 M (OE)). Each data set was fit to a single exponential to derive the amplitude of the single exponential. B, the single exponential rates were plotted against AZTTP concentration. The error bars show a high degree of standard error at low concentrations of nucleotide. The maximum polymerization rate of 0.2 s Ϫ1 was estimated from the rate of incorporation at higher AZTTP concentrations. C, the single exponential amplitudes were plotted as a function of AZTTP concentration. The fit of the data to a hyperbola yields a K d of 187 Ϯ 54 M.
serving the antiviral activity of the analog but allows low toxicity.
Incorporation of each of the anti-HIV nucleoside analogs proceeded at rates that were slower than the rates of incorporation of their natural nucleotide counterparts. The rates of incorporation of the analogs by Pol ␥ ranged from 38-fold (for ddATP versus dATP) to 97,000-fold slower (CBVTP versus dGTP) compared with their corresponding natural nucleotides. A variation in the strength of nucleotide binding was also observed. The range of values for ground state binding varied from 36-fold tighter to 300-fold weaker than natural nucleotides, ranging from the tight binding of ddCTP, d4TTP, and ddATP to the relatively weak binding of AZTTP. The ability of Pol ␥ to discriminate against incorporation of the analogs can be calculated from a ratio of the specificity constants for the natural nucleotide compared with the drug. An overall comparison of discrimination for each analog by Pol ␥ shows that if toxicity is based solely on incorporation by Pol ␥, then toxicity would range from ddCTP as the highest to CBVTP as the lowest toxicity drug.
It should be noted that the kinetics of AZTTP incorporation by Pol ␥ are unusual compared with the typical nucleotide concentration dependence of the rate of polymerization, and so the conclusions regarding AZT may not be valid. In our experiments, the enzyme and DNA are preincubated, and a mixture of nucleotide and Mg ϩ2 are added to initiate the polymerization reaction. The primer/template sequence allows one AZTMP incorporation opposite a template A. Therefore, the amplitude of the polymerization reactions illustrates the amount of enzyme-DNA complex that is able to rapidly bind nucleotide and form product during a single turnover of the enzyme. Dependence of the burst amplitude on AZTTP concentration suggests that the polymerization reaction is readily reversible, so that increasing concentrations of AZTTP drive the formation of more product in equilibrium at the active site. Accordingly, the assumptions inherent in the equality k pol /K d ϭ k cat /K m may not be valid. Further analysis of the mechanism of AZT incorporation is planned. Until then, the kinetic parameters summarized for AZT must be considered tentative and may underestimate the toxicity due to incorporation by Pol ␥. At the very least, one should note that in this assay as in others AZT appears to have unusual properties that warrant further exploration. Moreover, there is growing evidence that some of its toxicity may be due to interactions with other cellular components. Taken at face value, our data suggest that the toxicity of AZT is not attributable to effects on mitochondrial replication.
Recently Lim and Copeland (47) published a paper with conclusions that are qualitatively similar to those presented in our current and former work (36) . However, quantitatively the conclusions are quite different. Lim and Copeland (47) rely upon steady state measurements of incorporation using single nucleotide incorporation assays and report k cat values of 0.05 s Ϫ1 for correct incorporation. These values are 1000-fold lower that what we report and are clearly too low to represent a physiologically significant rate. Steady state single nucleotide incorporation assays define the rate of DNA release from the polymerase and not the rate of incorporation (26 -30) . Indeed the rates reported by Lim and Copeland (47) are comparable with the rates of DNA dissociation that we have observed for Pol ␥ (14). These errors are propagated to corresponding reductions in the K m values reported. Since K m reflects the balance between the rates of substrate binding and product release, the 100-fold lower K m values reported by Lim and Copeland (47) are a function of the slower k cat due to slow product release under the conditions of their measurement. However, the problems are compounded when comparisons are made to analogs, where the rate may actually reflect the slower rate of incorporation. Thus, their calculation of the discrimination involves a ratio of rates reflecting different steps in the pathway; that is, the rate of DNA release for correct incorporation is divided by the rate of incorporation for the analog. Exonuclease Removal of Analogs-Although Pol ␥ exhibits a wide range of selectivity for incorporation of each analog, only a 50-fold variation was observed in the rates of removal of the anti-HIV analogs from the 3Ј end of the primer, with the exception of ddC. The rates of excision of each analog other than ddC varied from 0.0004 to 0.02 s Ϫ1 . The excision of 26/45 DNA terminated with PMPA was examined in the presence of a DNA trap to test whether the PMPA-terminated DNA might remain bound to the enzyme before excision. No excision was observed in the presence of the trap, confirming that the faster rate of dissociation effectively allowed release of the DNA before excision (data not shown). Similar conditions may occur in vivo due to the high copy number of mitochondrial genomes. However, in the closed system of the mitochondria, as in the test tube, the DNA can rebind to the enzyme to allow excision at the slow rate. Nonetheless, depending upon the ratio of polymerase to DNA, the dissociation of the DNA before removal of the chain terminator may contribute to the observed toxicity.
The analog ddC was unique in that no cleavage of 3Ј-terminal ddCMP was observed, even after a 12-h incubation of the DNA with the enzyme (36) . Similarly, lack of cleavage of dideoxynucleotides has been observed for porcine liver Pol ␥ (for ddCMP) (48) and for yeast Pol ␥ (for ddTMP, AZTMP, and ddCMP) (49) . In agreement with these results, we observed a very low amplitude for the removal of ddAMP from the end of a chain-terminated primer, suggesting that it is a very poor substrate for the exonuclease. The slow hydrolysis or lack of hydrolysis of these analogs effectively reduces comparisons of Pol ␥ and HIV-1 RT to the fidelity of the two polymerases involving discrimination against incorporation of the various analogs at the polymerase active site. Further studies are under way to establish the basis for this exceedingly slow excision of ddCMP. The current results explain the high toxicity of ddC and suggest that analogs that activate the exonuclease reaction after their incorporation would be considerably less toxic. Toxicity Index-The toxicity of nucleoside analogs can be considered as arising from the effects stemming from slowing the rate of replication of the mitochondrial genome. Once the analog is incorporated, it stalls further replication until it is removed by the proofreading exonuclease. Given the interplay between the probability of termination, based upon the discrimination against the analog and the rate of removal by the exonuclease, we can calculate the extent to which the genome replication is slowed in the presence of each analog. For example, it may normally take 400 s to replicate the 16-kilobase genome at a rate of 40 nucleotides/s, and the contribution of the exonuclease to the overall rate is insignificant (37). In the presence of an equimolar concentration of (Ϫ)3TCTP relative to dCTP, for example, one would expect (16, 
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termination events during the time course of replication, based upon the measured discrimination reported in Table III and assuming that 1 in 4 template nucleotides is G. Given the rate of exonuclease removal of 0.015 s Ϫ1 , it would take, on the average, 1.4/0.015 ϭ 93 s to remove the chain terminators. Thus the total time required to replicate the genome would increase from 400 to 493 s. Accordingly, we can define a toxicity index as the increase in time required to replicate the genome by the ratio 493/400 ϭ 1.2 for (Ϫ)3TC. Thus, one predicts that the toxicity of (Ϫ)3TC should be quite low, commensurate with the physiological effect of the small change in the time required to replicate the genome. This simplified analysis does not account for the likelihood that cells replicating at a faster rate may be more sensitive to toxicity of nucleoside analogs, nor does it account for the multiple copy number of the mitochondrial genome, and we ignore any possible affects of temporary chain termination on gene expression. Nonetheless, the toxicity index appears to correlate with the toxicity of existing nucleoside analogs and should be useful in predicting toxicity of new compounds.
The formula for calculating the toxicity index can be simplified and generalized to the following form.
where k cat represents the rate of incorporation of the natural dNTP, k exo represents the rate of removal of the chain terminator, D is the discrimination as defined in Table III, [dNTP] is the concentration of correct nucleoside triphosphates, [AnaTP] is the concentration of the nucleoside analog in the triphosphate form, and the factor of four is included assuming one in four bases will properly base pair with the chain terminator. Calculations of the toxicity index are shown in Table IV for each of the analogs, assuming a ratio [AnaTP]/[dNTP] ϭ 1. The predicted toxicity will be lower for each analog in proportion to the lower concentration of phosphorylated nucleoside analog relative to correct dNTP, and so differences in mitochondrial uptake and phosphorylation will not be reflected in Table IV . Note also that a toxicity index of 1.0 defines zero toxicity, in that the rate of replication of the genome is unaffected. From the data summarized in Table IV , one can see that CBV, (Ϫ)3TC, and AZT are expected to be the least toxic.
Our studies indicate that PMPA may serve as an effective antiviral drug while exhibiting low mitochondrial toxicity. Pol ␥ discrimination against incorporation of PMPA ranked between (Ϫ)3TC and AZT, which are both relatively well tolerated by patients. PMPA effectively prevented SIV infection in macaques when treatment was given just before or after infection (50), and PMPA exhibits potent anti-HIV activity both in vitro and in vivo (51) . Recent phase III clinical results indicate no observed toxicity in patients after 48 weeks of therapy as well as an absence of HIV-1 RT mutations leading to drug resistance. 3 Additionally, recent studies show that PMPA treatment of macaques with SHIV KU early during infection results in development of a virus-specific immune response that controls viral replication after cessation of drug treatment (40, 41) .
Conversely, FIAU is a highly toxic nucleoside analog. FIAU treatment results in severe lactic acidosis and death in several patients (33) , resulting from mitochondrial toxicity. FIAUTP is efficiently incorporated opposite single template A residues (Fig. 7) , (52) , but Pol ␥ chain elongation was impaired when presented with several A residues (52). The mitochondrial genome contains many runs of dAMP residues, possibly leading to increased inhibitory effects of this drug at these sites of replication. FIAUTP effectively competes against dTTP for incorporation by Pol ␥ but does not cause termination of replication. Excision of FIAUMP from duplex DNA occurred at a rate similar to excision of a correct base pair (Fig. 9B) . This result may indicate that FIAUMP is not recognized as an improper substrate by Pol ␥ and can, therefore, be internalized by formation of a subsequent base pair. Although FIAU ranked with TABLE IV Toxicity index and rates of exonuclease removal of analogs by Pol ␥ Rates of removal of the analog monophosphate from the 3Ј end of the primer were measured in single turnover experiments. The toxicity index was calculated as described in the text and defines the increase in time required to replicate the mitochondrial genome. The low amplitude on the curve for ddAMP removal (and to a lesser extent PMPA and d4T) may make expected toxicity greater than what is suggested by the toxicity index. The toxicity index is shown separately for FIAU since it is not a chain terminator, and therefore, the computation does not have the same meaning. a Measured previously under conditions where chain-terminated primer template (1500 M) was in excess of holoenzyme (20 nM) (36) . It should be noted that under similar conditions, excision of CBVMP was found to be faster and comparable with the rate of 3TCMP removal. lower toxicity than ddC in our assay, the presence of the 3Ј OH in FIAU may lead to the increased toxicity experienced by patients in clinical trials. The mutagenic effects after internalization of this analog into DNA are not well defined but are likely to cause serious problems. Therapeutic Index-The ability of HIV-1 RT and Pol ␥ to correctly replicate a DNA sequence has been measured by monitoring mismatch formation in the presence of incorrect nucleotides (24, 27) . The overall fidelity of these enzymes is mismatch sequence-dependent and is 1 error in 3,500 -570,000 polymerization events for Pol ␥ (24) and 1 error in 1,700 -19,700 polymerization events for HIV-1 RT (27) . The higher fidelity of polymerization by Pol ␥ compared with HIV-1 RT may reflect the basis for susceptibility of HIV-1 RT to nucleoside analog incorporation, resulting in suppression of viral replication. Incorporation of the anti-HIV nucleoside analogs as well as PMPApp by HIV-1 RT has been examined under single turnover conditions (19 -21, 53, 54) . A comparison of the discrimination against analog incorporation exhibited by Pol ␥ and HIV-1 RT is presented in Table III by computing a theoretical therapeutic index. Data for analog incorporation into DNA/DNA and DNA/RNA duplexes is included because HIV-1 RT utilizes both primer/template combinations. The analogs are listed in the order of increasing discrimination by Pol ␥. The order of discrimination by HIV-1 RT against analog incorporation does not follow a similar pattern, and this divergence possibly explains the antiviral effectiveness and lower toxicity of (Ϫ)3TC, AZT, and CBV in patient treatment.
The maximum discrimination by HIV-1 RT is 149, favoring incorporation of dCTP compared with (Ϫ)3TCTP into a DNA/ RNA duplex. In contrast, a discrimination of 902,777 is observed against CBVTP incorporation by Pol ␥. A high discrimination against incorporation of a nucleoside analog by Pol ␥ compared with HIV-1 RT would indicate that drug serves as a highly specific HIV-1 RT inhibitor. This is illustrated by a high therapeutic index value, as calculated in Table III . Additionally, such a comparison may be a measure of predicting mitochondrial toxicity. For example, in our assay ddCTP is more inhibitory to Pol ␥ than HIV-1 RT,; and this analog causes the highest patient toxicity of the analogs approved to treat HIV infection. Similarly, CBVTP serves as a good substrate for HIV-1 RT incorporation compared with Pol ␥, and CBV may cause the lowest mitochondrial toxicity of approved nucleoside analogs (1, 55) .
The discrimination against analog incorporation exhibited by Pol ␥ in our in vitro studies directly correlates with toxicity of the analogs as measured by levels of mitochondrial replication (46), levels of mitochondrial DNA (1, 16, 56) , and cell viability and mitochondrial morphology (16) . Overall, ddC is consistently the most toxic analog in patient treatment and toxicity studies. AZT and CBV exhibit the lowest cell culture toxicity, correlating with high discrimination against incorporation by Pol ␥. A similar analysis of patient toxicity caused by each analog is difficult due to the use of multiple nucleoside analogs in reported clinical trials. Although differences exist between the analogs in phosphorylation, cellular uptake, and transport into the mitochondria, in vitro analysis of analog incorporation by Pol ␥ appears to provide a rapid screening tool to test compounds for potential toxicity to mitochondrial replication.
The discovery of nucleoside analogs with increased viral specificity is desirable, especially for long term management of AIDS. For instance, (Ϫ)3TC has only been recently used to treat AIDS, and availability of this drug results in better management of viral load. High level resistance against (Ϫ)3TC develops after 4 months of therapy (57) but leads to resensitization of previously AZT-resistant strains of the virus (58) . Our data suggest PMPA may be an effective HIV inhibitor by acting as a good substrate for HIV-1 RT inhibition and avoiding incorporation into the mitochondrial DNA by Pol ␥. Further toxicity studies and data from patient trials will be required to support this conclusion. But based on correlation between the results presented here and previous toxicity assays, it seems reasonable to suggest the experiments presented here serve as an effective screening tool for potential drug candidates. Studies such as the work presented here can contribute to the rational drug design of HIV-1 RT-specific analogs.
Our current protocol provides an enzyme preparation and methods to give a reliable estimate of nucleoside analog toxicity. Using these methods, new inhibitors can be quickly screened for potential toxicity without a major investment in resources and before extensive development. This screening should be part of nucleoside analog drug discovery protocol.
